Company Encyclopedia
View More
name
Thalys
603716.SH
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis system; automated chemiluminescence immunoassay system; and blood analyzer. The company was formerly known as Thalys Medical Technology Inc.
1.579 T
603716.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking72/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-22.27%E
    • Profit Margin-19.27%D
    • Gross Margin21.06%D
  • Growth ScoreE
    • Revenue YoY-34.22%E
    • Net Profit YoY-14.08%D
    • Total Assets YoY-33.31%E
    • Net Assets YoY-8.00%D
  • Cash ScoreE
    • Cash Flow Margin-518.91%E
    • OCF YoY-34.22%E
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreC
    • Gearing Ratio49.61%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Donghu High-tech Zone supports the research and development of key technologies for brain-computer interfaces, and multiple brain-computer interface concept stocks have received intensive research

    Wuhan East Lake High-tech Zone has released policies to support the development of the brain-computer interface industry, promoting technological innovation and application. Related concept stocks such as Thalys and Hanwei Electronics have seen significant increases, with some stocks doubling and others rising over 50%. In the second half of the year, multiple brain-computer concept stocks have received institutional research, and the financing situation for increased positions is good

    Zhitong·
    SZ
    300007
    +3.18%
    SH
    603716
    +0.99%
    Zhitong·
    SZ
    300007
    +3.18%
    SH
    603716
    +0.99%

    Thalys: Shareholder Shanghai Angze, holding over 5% of shares, plans to reduce its stake by no more than 2% of the company's shares

    Thalys announced that its shareholder Shanghai Angze, holding more than 5% of the shares, plans to reduce its holdings by no more than 4.2028 million shares of the company from October 30, 2025, to January 29, 2026, through centralized bidding and block trading, accounting for approximately 2% of the total share capital. The reason for the reduction is its own investment planning arrangements, and no price range is set

    Zhitong·
    SH
    603716
    +0.99%
    Zhitong·
    SH
    603716
    +0.99%

    Thalys corrects the equity structure of the capital increase and investment announcement of its subsidiary

    Thalys Medical Technology Group Co., Ltd. issued a correction announcement, rectifying errors in the shareholder names and shareholding ratios in the announcement regarding the capital increase and investment in its subsidiary disclosed on September 18. After the correction, the shareholding ratio of "Thalys Medical" is adjusted from 49.00% to 41.00%, and the shareholding ratio of "Weixin Biotechnology" is adjusted from 41.00% to 49.00%. The company apologizes for the inconvenience caused by the correction and will strengthen the review of information disclosure

    Zhitong·
    SH
    603716
    +0.99%
    Zhitong·
    SH
    603716
    +0.99%

    Innovative drug concept stocks show partial strength, Thalys hits the limit up

    Innovative drug concept stocks are showing strength in parts, with Thalys hitting the limit up, Cosunter rising over 7%, and EASTON BIOPHARMACEUTICALS, huahaipharm, JOINN, and Enhua Pharmaceutical following suit

    Zhitong·
    SH
    603127
    -0.07%
    HK
    06127
    +0.31%
    SZ
    300436
    +0.09%
    Zhitong·
    SH
    603127
    -0.07%
    HK
    06127
    +0.31%
    SZ
    300436
    +0.09%

    Innovative drug concept stocks fell in the afternoon, with Staidson BioPharm down over 10%

    Innovative drug concept stocks fell in the afternoon, with Staidson BioPharm down over 10%, Thalys nearing its limit down, Cosunter down over 9%, and ALK and Zhendong Pharmacy among the biggest decliners

    Zhitong·
    SZ
    002940
    -1.44%
    SZ
    300158
    -0.30%
    SZ
    300204
    +1.32%
    Zhitong·
    SZ
    002940
    -1.44%
    SZ
    300158
    -0.30%
    SZ
    300204
    +1.32%
    © 2025 Longbridge｜Disclaimer